20 December 2018
Bart-Jan Kullberg made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.
Bart-Jan Kullberg is classified in the new 'Cross-Field' category, meaning he has been cited in different fields. Clarivate Analytics wants to use this category to break down the “artificial walls of conventional disciplinary categories”.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Q fever antibody does not predict disease progression
6 July 2021 Joint study by Radboudumc, Jeroen Bosch Hospital and UMC Utrecht. read more
First Dutch professor of infectious disease outbreaks at Radboud university medical center
4 June 2021 Chantal Bleeker-Rovers about research on coronavirus, Q fever and other infectious diseases outbreaks read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection
17 February 2021 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more
Invasive fungal infections in influenza and COVID-19
8 July 2020 The Aspergillus fungus is found in the lungs of many COVID patients. A parallel occurs with influenza patients, who often develop a serious fungal infection. Although such a serious fungal infection seems to occur less frequently in COVID-patients, alertness remains necessary, read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection
29 June 2020 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more